Valneva (NASDAQ:VALN) Trading Down 6.7% - Here's Why

Key Points

• Valneva SE's shares fell 6.7% in trading on Monday, hitting a low of $8.28 before closing at $8.50, with trading volume significantly increasing by 186% from the average session.
• Analysts have mixed views on Valneva's stock, with Guggenheim lowering its target price to $14.00 while HC Wainwright maintains a "buy" rating with a target price of $17.00.
• Wells Fargo & Company MN raised its stake in Valneva by 14.3%, now holding approximately $1,079,000 worth of shares, reflecting confidence from institutional investors in the company.

Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report)'s share price fell 6.7% on Monday . The company traded as low as $8.28 and last traded at $8.50. 187,663 shares were traded during trading, an increase of 186% from the average session volume of 65,524 shares. The stock had previously closed at $9.11.

Analyst Ratings Changes

Separately, Guggenheim cut their price target on shares of Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, May 8th.

Valneva Stock Performance

The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.12 and a current ratio of 2.27. The company's 50 day moving average is $6.75 and its 200 day moving average is $6.71. The firm has a market cap of $955.73 million, a P/E ratio of -11.40 and a beta of 1.77.

Valneva (NASDAQ:VALN - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.11. Valneva had a negative net margin of 33.87% and a negative return on equity of 34.78%. The company had revenue of $54.84 million during the quarter, compared to the consensus estimate of $46.28 million. As a group, equities analysts predict that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. Wells Fargo & Company MN raised its position in Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) by 14.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 246,766 shares of the company's stock after acquiring an additional 30,859 shares during the period. Wells Fargo & Company MN owned approximately 0.30% of Valneva worth $1,079,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.